Shal’Artem Tablet 20/120mg (Anti-Malaria) x24

Shal’Artem Tablet 20/120mg is an antimalarial combination medication containing Artemether (20mg) and Lumefantrine (120mg). This artemisinin-based combination therapy (ACT) effectively treats acute uncomplicated malaria caused by Plasmodium falciparum, including drug-resistant strains.

Uses

Shal’Artem Tablet treats acute uncomplicated malaria infections, particularly those caused by Plasmodium falciparum. It’s effective against chloroquine-resistant strains and is recommended as first-line treatment in many malaria-endemic regions for both adults and children of appropriate weight.

Benefits

• Provides rapid parasite clearance from bloodstream
• Effective against multi-drug resistant malaria strains
• Quickly reduces fever and malaria symptoms
• Lowers risk of treatment failure compared to monotherapy
• Decreases likelihood of severe malaria complications
• Prevents development of drug resistance when used properly
• Shows high cure rates in clinical studies
• Well-tolerated by most patients
• Recommended by WHO for uncomplicated malaria treatment

How It Works

Artemether rapidly reduces parasite load by generating free radicals that damage parasite membranes, providing quick symptom relief. Lumefantrine works more slowly to eliminate remaining parasites, preventing recrudescence. This complementary action ensures effective parasite clearance and reduces resistance development.

Dosage

Take Shal’Artem with food or milk to enhance absorption. The second dose should be taken 8 hours after the first dose on day one, then at 12-hour intervals for the remaining days.

Duration of Action

Shal’Artem begins working within hours after administration. Most patients experience symptom improvement within 24-48 hours. Artemether has a short half-life and clears most parasites within 2-3 days, while Lumefantrine has a longer half-life, providing protection against recurrence for approximately 1-2 weeks.

Side Effects

Most patients tolerate Shal’Artem well. Common side effects include headache, dizziness, nausea, abdominal pain, and loss of appetite. Less common effects include fatigue, muscle pain, joint pain, and sleep disturbances. Most side effects are mild and resolve spontaneously without intervention.

Warning

Complete the full 3-day treatment course even if symptoms improve quickly. Shal’Artem may cause QT interval prolongation, potentially leading to cardiac arrhythmias in susceptible individuals. Avoid in patients with known QT prolongation. Seek medical attention for severe vomiting, irregular heartbeat, or signs of severe malaria including confusion or seizures.

Pregnancy and Breastfeeding

Shal’Artem can be used in the second and third trimesters of pregnancy. First trimester use should be considered only when benefits outweigh risks and other antimalarials are unsuitable. Limited data suggests it is safe during breastfeeding, though benefits typically outweigh potential risks in malaria-endemic regions.

Interaction

• May increase risk of QT prolongation with certain antiarrhythmics
• Potential reduced efficacy when taken with CYP3A4 inducers
• Possible increased side effects with CYP3A4 inhibitors
• May interact with hormonal contraceptives, reducing their effectiveness
• Grapefruit juice may increase drug concentration and side effects

Precaution

Use with caution in patients with cardiac disease, liver or kidney impairment, or electrolyte abnormalities. Avoid in patients with severe malaria or history of allergic reactions to artemisinin derivatives. Take with food or milk to maximize absorption. Complete the full treatment course to prevent resistance development and ensure parasite clearance.

Important Information

Shal’Artem does not prevent malaria transmission to others. Continue using protective measures against mosquito bites. If vomiting occurs within one hour of taking a dose, repeat the dose. Consult healthcare provider if symptoms persist after completing treatment. Store below 30°C in original packaging, protected from light and moisture.